Review Article| Volume 34, ISSUE 1, P13-28, February 2020

Current Role of Radiation Therapy in the Management of Malignant Central Nervous System Tumors

Published:October 28, 2019DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Hematology/Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ostrom Q.T.
        • Gittleman H.
        • Truitt G.
        • et al.
        CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015.
        Neuro Oncol. 2018; 20: iv1-iv86
        • Chang S.M.
        • Parney I.F.
        • Huang W.
        • et al.
        Patterns of care for adults with newly diagnosed malignant glioma.
        JAMA. 2005; 293: 557-564
        • Ruda R.
        • Bello L.
        • Duffau H.
        • et al.
        Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments.
        Neuro Oncol. 2012; 14: iv55-iv64
        • Louis D.N.
        • Ohgaki H.
        • Wiestler O.D.
        • et al.
        The 2007 WHO classification of tumours of the central nervous system.
        Acta Neuropathol. 2007; 114: 97-109
        • Louis D.N.
        • Perry A.
        • Reifenberger G.
        • et al.
        The 2016 World Health Organization classification of tumors of the central nervous system: a summary.
        Acta Neuropathol. 2016; 131: 803-820
        • Brown P.D.
        • Buckner J.C.
        • O'Fallon J.R.
        • et al.
        Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination.
        J Clin Oncol. 2003; 21: 2519-2524
        • Shaw E.
        • Arusell R.
        • Scheithauer B.
        • et al.
        Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study.
        J Clin Oncol. 2002; 20: 2267-2276
        • van den Bent M.J.
        • Afra D.
        • de Witte O.
        • et al.
        Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.
        Lancet. 2005; 366: 985-990
        • Shaw E.G.
        • Wang M.
        • Coons S.W.
        • et al.
        Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.
        J Clin Oncol. 2012; 30: 3065-3070
        • Buckner J.C.
        • Shaw E.G.
        • Pugh S.L.
        • et al.
        Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma.
        N Engl J Med. 2016; 374: 1344-1355
        • Fisher B.J.
        • Hu C.
        • Macdonald D.R.
        • et al.
        Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.
        Int J Radiat Oncol Biol Phys. 2015; 91: 497-504
        • Pignatti F.
        • van den Bent M.
        • Curran D.
        • et al.
        Prognostic factors for survival in adult patients with cerebral low-grade glioma.
        J Clin Oncol. 2002; 20: 2076-2084
        • van den Bent M.J.
        • Brandes A.A.
        • Taphoorn M.J.
        • et al.
        Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
        J Clin Oncol. 2013; 31: 344-350
        • van den Bent M.J.
        • Baumert B.
        • Erridge S.C.
        • et al.
        Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
        Lancet. 2017; 390: 1645-1653
        • Stupp R.
        • Hegi M.E.
        • Mason W.P.
        • et al.
        Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
        Lancet Oncol. 2009; 10: 459-466
        • Stupp R.
        • Taillibert S.
        • Kanner A.
        • et al.
        Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial.
        JAMA. 2017; 318: 2306-2316
        • NCCN
        National Comprehensive cancer Network clinical practice guidelines in oncology: central nervous system cancers. 2016; Version 1.
        (Available at:) (Accessed October 29, 2016)
        • Roa W.
        • Brasher P.M.
        • Bauman G.
        • et al.
        Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.
        J Clin Oncol. 2004; 22: 1583-1588
        • Roa W.
        • Kepka L.
        • Kumar N.
        • et al.
        International atomic energy agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme.
        J Clin Oncol. 2015; 33: 4145-4150
        NRG BN005 A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas.
        (Available at:) (Accessed September 12, 2018)
        BN005: Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma.
        (Available at:) (Accessed April 30, 2019)
        BN001: dose-Escalated Photon IMRT or proton beam radiation therapy versus standard-dose radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma.
        (Available at:) (Accessed April 30, 2019)
        • Cairncross G.
        • Wang M.
        • Shaw E.
        • et al.
        Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
        J Clin Oncol. 2013; 31: 337-343
        • Claus E.B.
        • Bondy M.L.
        • Schildkraut J.M.
        • et al.
        Epidemiology of intracranial meningioma.
        Neurosurgery. 2005; 57 ([discussion: 1088–5]): 1088-1095
        • Braganza M.Z.
        • Kitahara C.M.
        • Berrington de Gonzalez A.
        • et al.
        Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review.
        Neuro Oncol. 2012; 14: 1316-1324
        • Abedalthagafi M.
        • Bi W.L.
        • Aizer A.A.
        • et al.
        Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
        Neuro Oncol. 2016; 18: 649-655
        • Olar A.
        • Wani K.M.
        • Sulman E.P.
        • et al.
        Mitotic index is an independent predictor of recurrence-free survival in meningioma.
        Brain Pathol. 2015; 25: 266-275
        • Orton A.
        • Frandsen J.
        • Jensen R.
        • et al.
        Anaplastic meningioma: an analysis of the National Cancer Database from 2004 to 2012.
        J Neurosurg. 2018; 128: 1684-1689
        • Nanda A.
        • Bir S.C.
        • Maiti T.K.
        • et al.
        Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma.
        J Neurosurg. 2017; 126: 201-211
        • Sahm F.
        • Schrimpf D.
        • Olar A.
        • et al.
        TERT promoter mutations and risk of recurrence in meningioma.
        J Natl Cancer Inst. 2016; 108 (djv377)
        • Sahm F.
        • Schrimpf D.
        • Stichel D.
        • et al.
        DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
        Lancet Oncol. 2017; 18: 682-694
        • Rogers L.
        • Zhang P.
        • Vogelbaum M.A.
        • et al.
        Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.
        J Neurosurg. 2018; 129: 35-47
        BN003: observation or radiation therapy in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery.
        (Available at:) (Accessed April 30, 2019)
        • Lee J.Y.
        • Niranjan A.
        • McInerney J.
        • et al.
        Stereotactic radiosurgery providing long-term tumor control of cavernous sinus meningiomas.
        J Neurosurg. 2002; 97: 65-72
        • Nicolato A.
        • Foroni R.
        • Alessandrini F.
        • et al.
        Radiosurgical treatment of cavernous sinus meningiomas: experience with 122 treated patients.
        Neurosurgery. 2002; 51 ([discussion: 1159–1]): 1153-1159
        • Kondziolka D.
        • Flickinger J.C.
        • Perez B.
        Judicious resection and/or radiosurgery for parasagittal meningiomas: outcomes from a multicenter review. Gamma Knife Meningioma Study Group.
        Neurosurgery. 1998; 43 ([discussion: 413–4]): 405-413
        • Pollock B.E.
        • Stafford S.L.
        • Link M.J.
        • et al.
        Single-fraction radiosurgery for presumed intracranial meningiomas: efficacy and complications from a 22-year experience.
        Int J Radiat Oncol Biol Phys. 2012; 83: 1414-1418
        • Wojcieszynski A.P.
        • Ohri N.
        • Andrews D.W.
        • et al.
        Reirradiation of recurrent meningioma.
        J Clin Neurosci. 2012; 19: 1261-1264
        • Rogers L.
        • Jensen R.
        • Perry A.
        Chasing your dural tail: Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas: In regard to DiBiase et al. (Int J Radiat Oncol Biol Phys 2004;60:1515-1519).
        Int J Radiat Oncol Biol Phys. 2005; 62 ([author reply: 618–9]): 616-618
        • Borgelt B.
        • Gelber R.
        • Kramer S.
        • et al.
        The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group.
        Int J Radiat Oncol Biol Phys. 1980; 6: 1-9
        • Gaspar L.
        • Scott C.
        • Rotman M.
        • et al.
        Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.
        Int J Radiat Oncol Biol Phys. 1997; 37: 745-751
        • Sperduto P.W.
        • Kased N.
        • Roberge D.
        • et al.
        Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases.
        J Clin Oncol. 2012; 30: 419-425
        • Sirven J.I.
        • Wingerchuk D.M.
        • Drazkowski J.F.
        • et al.
        Seizure prophylaxis in patients with brain tumors: a meta-analysis.
        Mayo Clin Proc. 2004; 79: 1489-1494
        • Brown P.D.
        • Ballman K.V.
        • Cerhan J.H.
        • et al.
        Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial.
        Lancet Oncol. 2017; 18: 1049-1060
        • Mahajan A.
        • Ahmed S.
        • McAleer M.F.
        • et al.
        Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial.
        Lancet Oncol. 2017; 18: 1040-1048
        • Shaw E.
        • Scott C.
        • Souhami L.
        • et al.
        Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05.
        Int J Radiat Oncol Biol Phys. 2000; 47: 291-298
        • Brown P.D.
        • Pugh S.
        • Laack N.N.
        • et al.
        Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
        Neuro Oncol. 2013; 15: 1429-1437
        • Gondi V.
        • Pugh S.L.
        • Tome W.A.
        • et al.
        Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.
        J Clin Oncol. 2014; 32: 3810-3816
        • Gondi V.
        • Deshmukh S.
        • Brown P.D.
        • et al.
        Preservation of neurocognitive function (NCF) with conformal avoidance of the hippocampus during whole-brain radiotherapy (HA-WBRT) for brain metastases: preliminary results of phase III trial NRG oncology CC001.
        Int J Radiat Oncol Biol Phys. 2018; 102: 1607
        • Yamamoto M.
        • Serizawa T.
        • Shuto T.
        • et al.
        Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study.
        Lancet Oncol. 2014; 15: 387-395
        • Iuchi T.
        • Shingyoji M.
        • Sakaida T.
        • et al.
        Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.
        Lung Cancer. 2013; 82: 282-287
        • Magnuson W.J.
        • Lester-Coll N.H.
        • Wu A.J.
        • et al.
        Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis.
        J Clin Oncol. 2017; 35: 1070-1077
        • Tawbi H.A.
        • Forsyth P.A.
        • Algazi A.
        • et al.
        Combined nivolumab and ipilimumab in melanoma metastatic to the brain.
        N Engl J Med. 2018; 379: 722-730
        • Davies M.A.
        • Saiag P.
        • Robert C.
        • et al.
        Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
        Lancet Oncol. 2017; 18: 863-873